American Association for Cancer Research
00085472can183835-sup-213322_4_supp_5549572_ps7lpv.pdf (267.77 kB)

Supplementary Figure S5 from Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

Download (267.77 kB)
journal contribution
posted on 2023-03-31, 02:40 authored by Jorge Gómez-Miragaya, Ander Díaz-Navarro, Raul Tonda, Sergi Beltran, Luis Palomero, Marta Palafox, Lacey E. Dobrolecki, Chen Huang, Suhas Vasaikar, Bing Zhang, Gerburg M. Wulf, Alejandro Collado-Sole, Eva M. Trinidad, Purificación Muñoz, Laia Paré, Aleix Prat, Alejandra Bruna, Carlos Caldas, Joaquín Arribas, María Teresa Soler-Monso, Anna Petit, Judith Balmaña, Cristina Cruz, Violeta Serra, Miguel Angel Pujana, Michael T. Lewis, Xose S. Puente, Eva González-Suárez

Chr12p amplification predicts better response to carboplatin



Breast Cancer Research Foundation





Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with de novo and acquired resistance limiting patient's survival. To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was performed on matched TNBC patient-derived xenografts (PDX) sensitive to docetaxel and their counterparts that developed resistance in vivo upon continuous drug exposure. Most mutations, small insertions/deletions, and copy number alterations detected in the initial TNBC human metastatic samples were maintained after serial passages in mice and emergence of resistance. We identified a chromosomal amplification of chr12p in a human BRCA1-mutated metastatic sample and the derived chemoresistant PDX, but not in the matched docetaxel-sensitive PDX tumor. Chr12p amplification was validated in a second pair of docetaxel-sensitive/resistant BRCA1-mutated PDXs and after short-term docetaxel treatment in several TNBC/BRCA1-mutated PDXs and cell lines, as well as during metastatic recurrence in a patient with BRCA1-mutated breast cancer who had progressed on docetaxel treatment. Analysis of clinical data indicates an association between chr12p amplification and patients with TNBC/basal-like breast cancer, a BRCA1 mutational signature, and poor survival after chemotherapy. Detection of chr12p amplification in a cohort of TNBC PDX models was associated with an improved response to carboplatin. Our findings reveal tumor clonal dynamics during chemotherapy treatments and suggest that a preexisting population harboring chr12p amplification is associated with the emergence of docetaxel resistance and carboplatin responsiveness in TNBC/BRCA1-mutated tumors. Chr12p copy number gains indicate rapid emergence of resistance to docetaxel and increased sensitivity to carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival in TNBC/BRCA1 patients.